MTD vs. ROIV: Mettler-Toledo vs. Roivant Sciences Stock Comparison

Company Profile

Mettler-Toledo (MTD) and Roivant Sciences (ROIV) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MTD is classified in Life Sciences Tools & Services while ROIV is classified in Biotechnology.

Mettler-Toledo (MTD) has more than two decades of public-market history since November 14, 1997, whereas Roivant Sciences (ROIV) listed on December 8, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Mettler-Toledo (MTD) has no ROE value reported for this period; Roivant Sciences (ROIV) reports a negative figure of -8.52%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

Mettler-Toledo (MTD) at 22.25% converts revenue to bottom-line profit above its industry’s benchmark range, while Roivant Sciences (ROIV) at 0.00% keeps roughly the typical share for its industry.

Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Mettler-Toledo (MTD) reports 28.70%, ranking against industry peers normally.

Profitability Metrics

Growth

Mettler-Toledo (MTD) at 3.98% is around its peer norm for revenue growth, while Roivant Sciences (ROIV) at -71.57% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Mettler-Toledo (MTD) reports EPS growth of 3.88%, ranked against its industry; Roivant Sciences (ROIV) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Roivant Sciences (ROIV) at 16.72 carries current ratio above its industry’s typical mid-range, while Mettler-Toledo (MTD) at 1.10 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Roivant Sciences (ROIV) at 0.02 is near its industry mid-range for debt-to-equity ratio, while Mettler-Toledo (MTD) at 26.06 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Mettler-Toledo (MTD) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Mettler-Toledo (MTD) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Mettler-Toledo (MTD) trades at 37.38 times trailing earnings, ranked against its peers, while Roivant Sciences (ROIV) has no P/E ratio this period.

Mettler-Toledo (MTD) at 8.16 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.

Both look rich against book: Roivant Sciences (ROIV) at 6.64 sits in the upper P/B ratio quartile, and Mettler-Toledo (MTD) at 442.71 prices even higher, above its industry range.

Valuation Metrics